Sugi Predict

Sugi Predict / Compounds / SCHEMBL4397333

SCHEMBL4397333

SCHEMBL4397333

COc1ccc(/C=C/CO)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 2/20 0.59
▸ TUBB4A P04350 1/20 0.59
▸ TUBB P07437 1/20 0.59
▸ TUBA3C P0DPH7 1/20 0.59
▸ TUBA1B P68363 1/20 0.59
▸ TUBA4A P68366 1/20 0.59
▸ TUBB4B P68371 1/20 0.59
▸ TUBB3 Q13509 1/20 0.59
▸ TUBB2A Q13885 1/20 0.59
▸ TUBB8 Q3ZCM7 1/20 0.59
▸ TUBA3E Q6PEY2 1/20 0.59
▸ TUBA1A Q71U36 1/20 0.59
▸ TUBA1C Q9BQE3 1/20 0.59
▸ TUBB6 Q9BUF5 1/20 0.59
▸ TUBB2B Q9BVA1 1/20 0.59
▸ LMNA P02545 2/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18248381 1.00 TUBB1 (0.59) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4832259 0.82 TUBB4A (0.55) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4832256 0.82 TUBB4A (0.55) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6280908 0.79 TUBB4A (0.60) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6280901 0.79 TUBB4A (0.60) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4088454 0.78 TUBB4A (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4088452 0.78 TUBB4A (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29417883 0.78 TUBB4A (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL26300264 0.78 TUBB4A (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4387873 0.78 TUBB4A (0.48) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-20 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-11485710-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-11-01 — — US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-19 — — US disclosed
CN-112370452-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2021-02-19 — — CN disclosed
US-10899716-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-01-26 — — US disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 — — EP disclosed
EP-3298002-B1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-12-16 — — EP disclosed
CN-107624111-B Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-11-03 — — CN disclosed
EP-3298002-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2018-03-28 — — EP disclosed
WO-2016185423-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-11-24 — — WO disclosed
WO-2016185423-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-11-24 — — WO disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 — — US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 — — US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 — — EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 — — EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 — — WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 — — EP disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 TUBB1 4621/4885TUBB4A 4684/4885TUBB 4567/4885
US-20210253532-A1 Heterocyclic Amides as Kinase Inhibitors MAP3K19, MAP3K20, MAP3K1 TUBB1 2114/4885TUBB4A 2282/4885TUBB 2074/4885
US-20230120185-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 TUBB1 2114/4885TUBB4A 2282/4885TUBB 2074/4885
US-11485710-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 TUBB1 2114/4885TUBB4A 2282/4885TUBB 2074/4885
US-10899716-B2 Heterocyclic amides as kinase inhibitors MAP3K19, MAP3K20, MAP3K1 TUBB1 2114/4885TUBB4A 2282/4885TUBB 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.